STOCKUPSIDE.IO
Analyst Price Target Intelligence
← Full Rankings
← Back to rankings
Ranked #187 by analyst upside · 2026-09-16
ACRV
Acrivon Therapeutics, Inc.
Healthcare · Market Cap $78M · P/E 0x
ANALYST PRICE TARGET
+528.4%
implied upside to consensus target
Current Price $1.83
Consensus Target $11.5
Bull Target $19.0
Bear Target $7.0
Analysts Covering 6
ANALYST CONSENSUS - STRONG BUY
Strong Buy
3
Buy
3
Hold
0
Sell
0
52-Week Low $1.27
52-Week High $3.56
YTD Return -25.6%
FUNDAMENTALS
Market Cap $78M
P/E Ratio (TTM) N/A
Forward P/E N/A
EPS (TTM) $-1.75
PEG Ratio N/A
Dividend Yield N/A
Revenue (TTM) N/A
Profit Margin N/A
52-WEEK RANGE
52-Week Low $1.27
52-Week High $3.56
Current Price $1.83
Bear Target $7.0
Bull Target $19.0
● Now $1.83 ● Target $11.5
TRADING DATA
Avg Volume 384K
YTD Return -25.6%
Analyst Count 6
Consensus Strong Buy
Upside to Target +528.4%
Last Updated 2026-09-16

ANALYST SUMMARY

Acrivon Therapeutics, Inc. (ACRV) is currently trading at $1.83 with a Wall Street consensus price target of $11.5, implying potential upside of 528.4% over the next 12 months. 6 analysts currently cover ACRV, with a consensus rating of Strong Buy - 100% of analysts rate the stock a Buy or Strong Buy. The most bullish analyst has a price target of $19.0, while the most cautious has a target of $7.0.

ACRV operates in the Healthcare sector with a market capitalisation of $78M. The stock is down 25.6% year-to-date and is currently trading near the lower end of its 52-week range of $1.27 – $3.56.

SIMILAR STOCKS

Other Healthcare stocks with comparable size and valuation.

RECENT ANALYST CALLS

Upgrade/downgrade history for ACRV, with each firm's 90-day track record across all stocks we track. See full firm rankings →

Piper Sandler - Reiterated
Overweight → Overweight 2026-01-09 14% win rate (7 calls)
HC Wainwright & Co. reit
Buy → Buy 2025-11-25 31% win rate (48 calls)
Oppenheimer - Reiterated
Outperform → Outperform 2025-08-14 14% win rate (7 calls)
Jones Trading ↓ Downgrade
Buy → Hold 2025-05-16 57% win rate (14 calls)
Oppenheimer - Reiterated
Outperform → Outperform 2025-05-15 14% win rate (7 calls)
HC Wainwright & Co. reit
Buy → Buy 2025-03-28 31% win rate (48 calls)
Oppenheimer - Reiterated
Outperform → Outperform 2025-03-28 14% win rate (7 calls)
Cantor Fitzgerald reit
Overweight → Overweight 2025-03-26 40% win rate (10 calls)
HISTORICAL SNAPSHOT

Point-in-time data from StockUpside's daily snapshots. Tracks price, analyst target, upside %, consensus, and analyst count.

Loading…
ANALYST CONVICTION SCORE
42
out of 100
Coverage depth
15/30
Consensus clarity
0/30
Vote unanimity
25/25
Rating stability
2/15

Measures analyst agreement, not fundamental quality. A high score means analysts broadly agree on this call - not that the stock will go up.

See 4,000+ stocks ranked by analyst upside

StockUpside.io tracks analyst consensus price targets across thousands of US-listed stocks, updated every day. The full ranked list is available with a Pro subscription.

View Full Rankings →